Personal stories

The most common inflammatory skin disease causes scaly patches, blisters and severe itching, but it’s far more than just a cosmetic concern. Learn why Johnson & Johnson is focused on helping the millions living with this painful condition.

Since its launch, Johnson & Johnson has focused on helping make surgeries safer. Learn how this analytical microbiologist and her team are continuing in that tradition with a digital app that aims to change the way medical devices are designed and sterilized.

Up to 5 million people worldwide live with this complex autoimmune condition, which is more prevalent in women and has a greater disease severity in Latin Americans and patients of African ancestry. Learn how Johnson & Johnson is working to innovate treatments for autoimmune diseases.

J&J provides annual scholarships to the program to elevate, empower, and advocate for the nursing profession.

Andreas Gerber, Worldwide Vice President of Oncology, shares Johnson & Johnson’s bold ambition to get in front of cancer. Read about the company’s success in hematologic malignancies, new pivotal data at this year’s ASH Annual Meeting, and important key takeaways.

Learn more about Robert Zhao, Ph.D, his partnership with Johnson & Johnson and antibody-drug conjugates—a new type of cancer therapy that targets and kills cancer cells without harming healthy cells.

Kimberly Alexander, Michelle Ware-Ivy and Marsha Calloway-Campbell learned firsthand that Black individuals develop multiple myeloma at higher rates. That’s why they joined Johnson & Johnson’s That’s My Word® health equity campaign, which builds awareness about the disparities surrounding this rare blood cancer.

In the just-released 2024 Access to Medicine Index, the company ranks among the top 5 improving access to medicines.

October 2024 Newsletter: Supporting the early-stage healthcare innovation ecosystem